Stocks Health care ATOS
NASDAQ · Health careAtossa Therapeutics, Inc. (ATOS)
It posted a net loss of $37.7M. In fiscal 2025 capital spending exceeded operating cash flow by $29.8M. At June 30, 2026 it held $26.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
What Atossa Therapeutics, Inc. does
Atossa Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ATOS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$34.8M | -$4.04 | -$29.8M |
| 2024 | n/a | -$25.5M | -$3.04 | -$21M |
| 2023 | n/a | -$30.1M | -$3.65 | -$21M |
| 2022 | n/a | -$27M | -$3.19 | -$20.8M |
| 2021 | n/a | -$20.6M | -$2.74 | -$16.5M |
| 2020 | n/a | -$17.8M | -$29.94 | -$11.6M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Atossa Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- August 7, 2026
- August 7, 2026
- June 12, 2026
- June 11, 2026
- May 8, 2026Exhibits 8-K
- May 8, 2026
- May 8, 2026
- April 16, 2026Other event 8-K
- March 30, 2026
Insider trades
What the people running Atossa Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 12, 2026 | Cigler TessaDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Galli Stephen JDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Finn JonathanDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Remmel H. LawrenceDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Chen Shu-ChihDirector | Received as pay | 10,000 | - |
| May 12, 2026 | Steinhart Richard IDirector | Received as pay | 10,000 | - |
Who owns ATOS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
6 insiders reported holding 62,355 shares in total, about $118.5K at the last price.
| Holder | Shares |
|---|---|
| Finn JonathanDirector | 11,666 |
| Remmel H. LawrenceDirector | 10,683 |
| Galli Stephen JDirector | 10,006 |
| Steinhart Richard IDirector | 10,000 |
| Chen Shu-ChihDirector | 10,000 |
| Cigler TessaDirector | 10,000 |
Questions about ATOS
What does Atossa Therapeutics, Inc. do?
Atossa Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ATOS.
Is Atossa Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $37.7M.
When did Atossa Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 18, 2026.
Similar companies
Compare ATOS with
Follow ATOS
Get an email when Atossa Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ATOS: get an email when it filesWhere the numbers come from
Financial figures are the values Atossa Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.